对针对尖峰-ACE2相互作用的抗冠状病毒药物的专利审查 (2019年至今)

Xing Huang1, Heng Gao1, Jiwei Zhang1

  • 1Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.

概括

研究人员审查了抗胰岛素转化酶2 (ACE2) 受体和spike (S) 蛋白相互作用机制的新冠病毒入口. 开发ACE2-S接口抑制剂是控制SARS-CoV-2和预防未来流行病的关键.